PBRM1 and neoplasm: In the CheckMate-214 trial, PD-L1 IHC, whole exome sequencing and RNA sequencing were performed to evaluate PD-L1 positivity, tumor mutation burden, indel burden, human leucine antigen class I zygosity, the PBRM1 mutation status, and gene signature scores (4).